I don't think that the validation will find that the machine is "crap" but it is one of the first of it's kind, hence the "II".
What I mean is, it took lots of improvements to go from a Wright Bros. airplane to an F-16 fighter. Although the unit may show promise it might take some improvements to become "state of the art".
My point is, when you have been a "start up" company for over twenty years the market adopts a "ho hum" attitude toward all of your accomplishments that do not include revenue and growth.
Planning should be under way if not completed for the anticipated validation (about how we will use this to produce revenue and growth) so that when the day comes, mgmt. doesn't have to ask, "Ok, now what?"
Also, design work should have already begun on the human sized Nano MRX machine to facilitate transition into human clinical trials.
I'm not saying that institutional investors won't take positions but they'll want to see revenue potential on this side of the horizon.